There are more than 100 types of cancers In Part II, head and neck cancer is d- affecting all parts of the human body. cussed. The global number of annual new More than 11 million people are diagnosed cases of this malignancy is ~500,000. These with cancer every year, and it is estimated malignancies include oral squamous cell that there will be 16 million new cases by carcinoma, salivary gland tumors, tons- the year 2020. In 2005, 7. 6 million peo- lar cancer, tongue cancer, nasopharyngeal ple died of cancer, that is, 13% of the 58 carcinoma, and retinoblastoma, which are million deaths worldwide. It is estimated detailed. In Part III, diagnosis, therapy, and that 9 million people will die from can- prognosis of thyroid carcinoma are d- cer worldwide in 2015 and 11. 4 million cussed. The global number of new cases of will die in 2030. More than 70% of all thyroid cancer is ~141,000, and the number cancer deaths occur in low and middle of worldwide thyroid mortalities is ~35,375. income countries. These statistics underlie The number of new cases of this cancer in the fact that cancer is the deadliest of all the United States is ~33,550. Molecular human diseases. The enormity of the glo- genetics of thyroid cancer, gene expr- bal healthcare costs as a result of cancer sion markers for diagnosis, papillary t- cannot be overemphasized.

InhaltsangabePART I. GENERAL METHODS AND OVERVIEWS Diagnosis 1. ROLE OF RNA INTERFERENCE IN UNDERSTANDING THE MOLECULAR BASIS OF CANCER; Jeffrey P. MacKeigan and Alex Gaither MECHANISM OF RNA INTERFERENCE RNA INTERFERENCE AS A CELL BASED SCREENING TOOL RNA INTERFERENCE TO UNDERSTAND COMPOUND MECHANISM OF ACTION COMPOUND SENSITIZATION, COMBINATION STRATEGIES AND SYNTHETIC LETHAL RNA INTERFERENCE SCREENS PROBLEMS ASSOCIATED WITH RNA INTERFERENCE BASED APPROACHES REFERENCES 2. CANCER BIOMARKERS (AN OVERVIEW); William C.S. Cho INTRODUCTION EMERGING TECHNOLOGIES FOR CANCER BIOMARKER DISCOVERY DNA Microarray Serial Analysis of Gene Expression MicroRNA Microarray Two Dimensional Polyacrylamide Gel Electrophoresis Free Flow Electrophoresis Capillary Electrophoresis MatrixAssisted Laser Desorption/Ionization TimeofFlight Mass Spectrometry SurfaceEnhanced Laser Desorption/Ionization TimeofFlight Mass Spectrometry Liquid Chromatography Coupled with Tandem Mass Spectrometry Linear Ion Trap Quadrupole-Orbitrap Imaging Mass Spectrometry IsotopeCoded Affinity Tags Multiple Reaction Monitoring Absolute Quantification of Proteins Protein Microarray Tissue Array Bioinformatics CURRENTLY USED CANCER BIOMARKERS BIOMARKERS FOR THE DIAGNOSIS OF CANCERS Genomicbased Biomarkers in Cancer Transcriptomic-based Biomarkers in Cancer Proteomicbased Biomarkers in Cancer BIOMARKERS FOR THE TREATMENT AND PROGRESSION OF CANCERS Genomicbased Biomarkers in Cancer Transcriptomic-based Biomarkers in Cancer Proteomicbased Biomarkers in Cancer BIOMARKERS FOR THE PROGNOSIS OF CANCERS Genomicbased Biomarkers in Cancer Transcriptomic-based Biomarkers in Cancer Proteomicbased Biomarkers in Cancer CHALLENGES AND PERSPECTIVES REFERENCES 3. TUMOR ANGIOGENESIS IN CANCERS: EXPRESSION OF CD105 MARKER; Osamu Tokunaga, Rahmawati Minhajat, and Daisuke Mori INTRODUCTION MORPHOLOGICAL FEATURES OF TUMOR ANGIOGENESIS DETECTION OF THE ENDOTHELIUM IMMUNOHISTOLOGY Antigenecity Retrieval Immunohistology SIMULTANEOUS MASS AND COMPARATIVE STUDY: TISSUE ARRAY SPECIFIC MARKERS FOR VASCULAR ENDOTHELIUM IN TUMORS Angiogenesis CD105/ENDOGLIN ENDOTHELIAL MARKER SPECIFIC FOR NEWLY FORMED BLOOD VESSELS CD105 AND VASCULOGENESIS ORGAN SPECIFICITY OF CD105 POSITIVE TUMOR ANGIOGENESIS APPLICATION OF CD105 FOR ANTI-ANGIOGENIC CANCER THERAPY REFERENCES 4. SPINDLE CELL ONCOCYTOMA OF THE ADENOHYPOPHYSIS: INTEGRATED CLINICOPATHOLOGIC DIAGNOSIS BY IMAGING, HISTOLOGY, AND IMMUNOHISTOCHEMISTRY; Istvan Vajtai and Rahel Sahli INTRODUCTION CLINICAL PRESENTATION IMAGING ASPECTS HISTOLOGY AND IMMUNOPHENOTYPE DIFFERENTIAL DIAGNOSIS THERAPEUTIC AND PROGNOSTIC IMPLICATIONS DISCUSSION AND PERSPECTIVES REFERENCES 5. DISSEMINATED CARCINOMA OF UNKNOWN PRIMARY SITE: DETECTION WITH F-FLUORODEOXYGLUCOSE- POSITRON EMISSION TOMOGRAPHY; Pascal Sève and John R. Mackey INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES 6. UNKNOWN LYMPHADENOPATHY: DIAGNOSIS USING AN ENDOSCOPIC ULTRASOUND-GUIDED FINE-NEEDLE ASPIRATION; Ichiro Yasuda INTRODUCTION APPLICATION EQUIPMENT PROCEDURE DIAGNOSTIC YIELD REFERENCES Therapy 7. PRETARGETED RADIOIMMUNOTHERAPY IN CANCER: AN OVERVIEW; Stefano Papi, Chiara Maria Grana, Mirco Bartolomei, Laura Ravasi, Marta Cremonesi, Mahila Ferrari, Luigi Martano, Lucia Garaboldi, Marco Chinol, and Giovanni Paganelli INTRODUCTION THERAPEUTIC RADIOISOTOPES LIMITATIONS OF CLASSICAL

Hersteller:
Springer Verlag GmbH
juergen.hartmann@springer.com
Tiergartenstr. 17
DE 69121 Heidelberg